The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
Official Title: An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
Study ID: NCT02726009
Brief Summary: The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring androgen deprivation therapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
S. P Medical College and AG of Hospitals, Bikaner, Rajasthan, India
Krishna Institute of Medical Sciences, Secunderabad, Telangana, India
Bodyline Hospitals, Ahmedabad, , India
HCG Multi Specialty Hospital, Ahmedabad, , India
Shalby Hospital, Ahmedabad, , India
HealthCare Global Enterprises Limited, Bangalore, , India
KLE's Dr. Prabhakar Kore Hospital & MRC, Belgaum, , India
Apollo Speciality Hospital, Chennai, , India
Rajiv Gandhi Cancer Institute and Research Centre, Delhi, , India
Muljibhai Patel Urological Hospital, Gujrat, , India
CHL Hospital, Indore, , India
SMS Medical College & Attached Hospital's, Jaipur, , India
Tata Medical Center, Kolkata, , India
King's George Medical University, Lucknow, , India
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, , India
Tata Memorial Hospital, Mumbai, , India
Government Medical College and Super Specialty Hospital, Nagpur, , India
Rml & Pgimer, New Delhi, , India
Aman Hospital and Research Center, Vadodara, , India
Name: Global Clinical Compliance
Affiliation: Ferring Pharmaceuticals
Role: STUDY_DIRECTOR